Form D · Biotechnology
RevivBio Inc.
Cambridge, MA · CIK 0001935963
Offering snapshot reported Jan 16, 2024 · SEC filing
- Reported sold
- $2.95M Offering amount: $3.15M
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 29, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 16, 2024 | Initial | $2,954,976 | No comparison | 11 | SEC filing |
| Oct 4, 2022 | Amendment | $400,000 | $263,000vs Jul 5, 2022 | 6 | SEC filing |
| Jul 5, 2022 | Initial | $137,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-502521
Amount Offered and Sold include the conversion of SAFE's.
Source: Form D, filed Jan 16, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Oxana Kukhaneva | Director |
| Fatemeh Aileen Mastouri | Director, Executive |
| Karla Milcic | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
750 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139